Jackson Laboratory

The Jackson Laboratory, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine, provides genetically engineered mouse models, specialized research animals, animal husbandry services, induced pluripotent stem cell lines, genomic sequencing, and translational research support to the federal government as a prime contractor on multiple contracts and grants and as a subrecipient on federal grants.

Jackson Laboratory operates across 76 federal agencies without SBA set-asides, competing on scientific capability and institutional expertise rather than business-size classifications. The organization's federal portfolio spans 3,154 awards (96% prime, 4% sub) with combined potential value of $625.8 million, though obligated dollars total $1.92 billion, reflecting large IDIQs placed against multiple federal science agencies and the National Institutes of Health. Activity has trended downward recently—27 awards in 2026 year-to-date compared to 100 in 2024—reflecting typical concentration around large IDV ordering periods rather than declining market position.

Customer concentration centers on NIH institutes and components. The top five customers by potential value account for 71% of combined potential dollars: NIH Office of Logistics and Acquisition Operations (172 awards, $163.5 million), the National Institute of Allergy and Infectious Diseases ($147.8 million across 49 awards), the Defense Health Agency ($60.5 million), the National Institute of Environmental Health Sciences ($43.5 million), and the Army Medical Command ($31.1 million). By award count, the Office of the Director leads with 197 awards, signaling volume in smaller research grants and cooperative agreements alongside the mega-IDIQs anchoring dollar value.

Jackson Laboratory holds four significant IDVs: a $146.3 million single-award contract with NIAID through July 2031 for pre-clinical infectious disease models covering small animal models, non-human primate models, animal replacement/non-traditional models, and specialized reagents; a $35 million Defense Health Agency Blanket Purchase Agreement through July 2030 for small laboratory research animals; a $4.5 million NIEHS IDC through June 2029 for barrier-reared rodents; and a $75.6 million indefinite-delivery contract with Veterans Integrated Service Network 22 for CD34 mice models extending through June 2026. Task order volume on the NIAID contract exceeds 29 orders; the Defense Health Agency BPA carries 12 BPA calls.

Capability work centers on genetically engineered mouse models and associated research services. Representative recent contracts include a $2.99 million purchase order from the National Institute on Aging (September 2026) to expand, curate, and distribute up to 936 isogenic Alzheimer's disease and related dementias induced pluripotent stem cell lines under the iPSC Neurodegenerative Disease Initiative with three optional renewal years; a $1.53 million purchase order from NIA (August 2025) for iPSC lines supporting the Neurodegeneration Initiative; a $650 thousand definitive contract from the National Institute of Child Health and Human Development (September 2025) to establish and operate a repository of Down syndrome mouse models; and a $6 million definitive contract from NIA (September 2023) for iPSC engineering services. Contract awards span NIH institutes, the Defense Health Agency, the Veterans Affairs system, the Army Medical Command, the CDC, and the FDA, reflecting broad reach across federal biomedical research.

Federal grant activity is substantial, with Jackson Laboratory serving as prime recipient on over 100 NIH and Defense Health Agency project grants across aging research, neurodegenerative disease, cancer biology, immunology, genomics workforce development, and infrastructure development. Representative grants include a $932,993 NIAID award (June 2026) investigating trained immunity signatures in older adults, a $716,579 NIA grant (December 2025) on microglia-mediated synapse loss in Alzheimer's disease, a $601,272 Defense Health Agency cooperative agreement (August 2025) on spatial transcriptomics of tumor-infiltrating immunocytes in melanoma, and a $486,750 NIH grant (July 2026) on reporter mouse models for in vivo gene editing. Jackson Laboratory also serves as subrecipient on university-led grants, particularly supporting iPSC generation, genomic analysis, animal breeding, and bioinformatics work at institutions including University of Connecticut Health Center, Yale University, Brigham and Women's Hospital, Emory University, and Washington University.

Service Contract Inventory reporting covers eleven prime and two subcontractor records across FY2022–FY2024, capturing federal service contracts above the $150,000 threshold. SCI-reportable invoiced revenue totaled $9.4 million across the three years: $2.1 million in FY2022 (8.2 FTEs), $3.2 million in FY2023 (9.7 FTEs), and $4.1 million in FY2024 (12.4 FTEs). Government-paid hourly rates on federal services contracts averaged $131.33/hr at the median, ranging from $108.26/hr at the tenth percentile to $197.67/hr at the ninety-fifth percentile, reflecting the specialized expertise embedded in genomics, animal model development, and translational research services. Across SCI-reported prime contracts, subcontractors performed negligible hours, indicating Jackson Laboratory builds delivery teams in-house rather than relying on subcontracting for core research and animal services. The SCI dataset represents a small slice of Jackson Laboratory's total federal revenue—contract and grant awards shown here carry much larger dollar values—because SCI excludes products, goods, grants, and non-federal revenue.